Nasdaq · Healthcare
Orchestra BioMed Holdings, Inc. (OBIO)
As-reported financials and recent SEC filings for Orchestra BioMed Holdings, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$33.5M
Net income
$-52.7M
Net margin
—
Diluted EPS
$-1.11
ROE
-98.4%
P/E (TTM)
—
Market cap
—
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-51.8M | $-64.3M | $-51.5M | $-32.7M | $-394,756 |
| Net income | $-52.7M | $-61.0M | $-49.1M | $-33.6M | $-378,753 |
| Diluted EPS | $-1.11 | $-1.66 | $-1.48 | $-1.12 | $-0.01 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →1442026-07-01
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →Largest Healthcare peers
Go deeper on OBIO
Search Orchestra BioMed Holdings, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.